Global Polycystic Ovarian Syndrome Treatment Market

Global Polycystic Ovarian Syndrome Treatment Market Size, Trends, and Analysis - Forecasts To 2026 By Drugs (Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants, Anti-obesity), By Surgery (Ovarian Wedge Resection, Laparoscopic Ovarian Drilling), By Region (North America, Asia Pacific, CSA, Europe, and the Middle East and Africa); End-User Landscape, Company Market Share Analysis & Competitor Analysis

Category Healthcare

Format

This report was recently updated on December 19 2024 with the latest and most recent market numbers

Polycystic Ovarian Syndrome Treatment Market: Insights

PCOS (polycystic ovary syndrome) is a hormonal endocrine disease that causes to females aged 15 to 49 years old. The appearance of lumps on the ovaries is a sign of this disease, which contributes to a deficiency of the ovulation-initiating hormone in the women's body. Since there are no specific medications for the disease, the primary goal of the treatment strategy is to reduce the effects of the disease. According to the CDC (Centers for Disease Control and Prevention), polycystic ovary syndrome is the most common cause of woman infertility.

Moreover, if the disease is not treated promptly, it can cause metabolic disorders that can lead to the onset of type-2 Diabetes. The severity of the disease raises the risk of patients developing severe endometrial and uterine cancers. As a result, early detection and proper treatment are necessary for a complete recovery. Since this disease has such a wide variety of complications, there are many medications and therapies available to treat them. As a result, industry leaders are driving the development of new drugs and therapies. The growing cases of patients who are suffering from polycystic ovary syndrome are driving the global demand for PCOS treatment to accelerate.

The PCOS market is growing, leading to a rise in the rate of PCOS, increased patient awareness, and increased use of standard treatment. Furthermore, the ease of access to PCOS therapies, the increase in demand for PCOS drugs, and technical advances in PCOS detection all have a significant positive impact on the market expansion. The lack of licensed therapeutics, and also the uncertain pathophysiology and etiology of PCOS, are estimated to slow market development. Besides this, during the forthcoming years, emerging economies' untapped opportunity poses attractive prospects for the expansion of the polycystic ovarian syndrome treatment industry. Besides that, the absence of a standardized medication for PCOS disease is likely to limit market expansion.

Furthermore, the industry's leaders are presently focused on the overall market unmet needs and enhancing their pipelines to capitalize on possibilities; the commercialization of all these strong pipelines is anticipated to spur market development. In addition, many private and government-sponsored programs to raise disorder awareness have been introduced, which is estimated to grow during the forecast period.

The COVID-19 pandemic, on the other hand, has had repercussions for many surgical operations, including laparoscopic ovarian drilling. Experts at the University of Birmingham-led NIHR Global Research Health Unit on Global Surgery released their findings in May 2020, stating that patients undergoing surgery after contracting coronavirus are at an elevated risk of postoperative complications.

global polycystic ovarian syndrome treatment market

Polycystic Ovarian Syndrome Treatment Market: By Drugs

Based on the drugs, the polycystic ovarian syndrome treatment market segment is divided into oral contraceptives, antiandrogen, insulin-sensitizing agents, antidepressants, and anti-obesity. Owing to the increased use of insulin-sensitizing agents as its first-line therapy for the treatment of PCOS, the insulin-sensitizing agent category is currently the largest revenue contributor and is expected to rise significantly during the prediction period.

The oral contraceptive pills market is also predicted to rise at a fast pace. Drospirenone, Medroxyprogesterone Acetate, & Ethinyl Estradiol are the most popular commercially accessible oral contraceptives. These OCPs are often used to cure Polycystic ovary syndrome complications such as prolonged or missing menstrual cycles, extreme menstrual cramps, Premenstrual syndrome (PMS), and acne. As a result, during the anticipated timeline, demand for OCPs is projected to grow at the fastest pace.

Polycystic Ovarian Syndrome Treatment Market: By Surgery

Based on the surgery, the polycystic ovarian syndrome treatment market segment is divided into ovarian wedge resection and laparoscopic ovarian drilling. The laparoscopic ovarian drilling is predicted to expand at the fastest pace during the estimated period. In critical situations, laparoscopic ovarian drilling is among the most frequent surgeries conducted by surgeons. As PCOS is a main cause of infertility in women, and drug reaction deteriorates over time, surgery using a thin microscope through the abdomen is widely preferred across the globe.

asia pacific polycystic ovarian syndrome treatment market

Polycystic Ovarian Syndrome Treatment Market: By Region

As per the geographical analysis, the market can be classified into North America (the United States, Canada, and Mexico), Asia Pacific (India, China, Japan, Malaysia, Singapore, and Rest of Asia Pacific), Europe (Germany, United Kingdom, Italy, France, Spain, Netherlands, and Rest of Europe), Middle East & Africa (Saudi Arabia, United Arab Emirates, and Rest of the Middle East & Africa) and Central & South America (Brazil, Argentina, and Rest of Central and South America). During the forecasted timeframe, the North American region is expected to lead the global economy.

Over the forecast period, Asia Pacific is expected to grow at a rapid pace. Improvements in healthcare infrastructure, an increase in the number of target populations, a growing R&D sector, an increase in healthcare reforms, and technical breakthroughs in the field of healthcare all contribute to industry growth.

Polycystic Ovarian Syndrome Treatment Market: Share & Competitor Analysis

Allergan plc, Pfizer Inc., Bayer AG, AstraZeneca plc., Bristol-Myers Squibb Company, Mylan N.V., Johnson and Johnson, Novartis AG, Teva Pharmaceutical Industries, and SANOFI, among others, are major players in the polycystic ovarian syndrome treatment market.

Please note: This is not an exhaustive list of companies profiled in the report.

In January 2020, Evotec SE and Bayer AG introduced a new five-year, multi-target agreement with Celmatix Inc. to produce several therapeutic alternatives for the diagnosis of PCOS, which is anticipated to accelerate the demand over the forecasted timeframe

In January 2020, Abbvie had an ongoing clinical study of the drug Elagolix in the pipeline, which is being tested for its protection and effectiveness in females with polycystic ovary syndrome. The company is now evaluating the efficacy and safety of Elagolix in females with polycystic ovarian syndrome in Phase 2 multicenter, double-blind, randomized, placebo-controlled experiment (PCOS).

Chapter 1 Methodology

1.1 Market Scope & Definitions

1.2 Estimates & Forecast Calculation

1.3 Historical Data Overview and Validation

1.4 Data Sources

1.4.1 Secondary

1.4.2 Primary

Chapter 2 Report Outlook

2.1 Global Polycystic Ovarian Syndrome Treatment Industry Overview, 2019-2026

2.1.1 Industry Overview

2.1.2 Drugs Overview

2.1.3 Surgery Overview

2.1.4 Regional Overview

Chapter 3 Polycystic Ovarian Syndrome Treatment Market Trends

3.1 Market Segmentation

3.2 Industry Background, 2019-2026

3.3 Market Key Trends

3.3.1 Positive Trends

3.3.1.1 Increase in prevalence of PCOS

3.3.1.2 Increase in number of pipeline drugs

3.3.2 Industry Challenges

3.3.2.1 Lack of approved therapeutics for the treatment of PCOS

3.4 Prospective Growth Scenario

3.4.1 Growth opportunities in emerging markets

3.5 COVID-19 Influence over Industry Growth

3.6 Porter’s Analysis

3.7 PESTEL Analysis

3.7 Value Chain & Supply Chain Analysis

3.9 Regulatory Framework

3.9.1 North America

3.9.2 Europe

3.9.3 APAC

3.9.4 LATAM

3.9.5 MEA

3.10 Technology Overview

3.11 Market Share Analysis, 2020

3.11.1 Company Positioning Overview, 2020

Chapter 4 Global Polycystic Ovarian Syndrome Treatment Market, By Drugs

4.1 Drugs Outlook

4.2 Oral Contraceptives

4.2.1 Market Size, By Region, 2019-2026 (USD Billion)

4.3 Antiandrogen

4.3.1 Market Size, By Region, 2019-2026 (USD Billion)

4.4 Insulin-Sensitizing Agents

4.4.1 Market Size, By Region, 2019-2026 (USD Billion)

4.5 Antidepressants

4.5.1 Market Size, By Region, 2019-2026 (USD Billion)

4.6 Anti-obesity

4.6.1 Market Size, By Region, 2019-2026 (USD Billion)

Chapter 5 Global Polycystic Ovarian Syndrome Treatment Market, By Surgery

5.1 Surgery Outlook

5.2 Ovarian Wedge Resection

5.2.1 Market Size, By Region, 2019-2026 (USD Billion)

5.2 Laparoscopic Ovarian Drilling

5.2.1 Market Size, By Region, 2019-2026 (USD Billion)

Chapter 6 Global Polycystic Ovarian Syndrome Treatment Market, By Region

6.1 Regional outlook

6.2 North America

6.2.1 Market Size, By Country 2019-2026 (USD Billion)

6.2.2 Market Size, By Drugs, 2019-2026 (USD Billion)

6.2.3 Market Size, By Surgery, 2019-2026 (USD Billion)

6.2.4 U.S.

6.2.4.1 Market Size, By Drugs, 2019-2026 (USD Billion)

6.2.4.2 Market Size, By Surgery, 2019-2026 (USD Billion)

6.2.5 Canada

6.2.5.1 Market Size, By Drugs, 2019-2026 (USD Billion)

6.2.5.2 Market Size, By Surgery, 2019-2026 (USD Billion)

6.3 Europe

6.3.1 Market Size, By Country 2019-2026 (USD Billion)

6.3.2 Market Size, By Drugs, 2019-2026 (USD Billion)

6.3.3 Market Size, By Surgery, 2019-2026 (USD Billion)

6.3.4 Germany

6.3.4.1 Market Size, By Drugs, 2019-2026 (USD Billion)

6.2.4.2 Market Size, By Surgery, 2019-2026 (USD Billion)

6.3.5 UK

6.3.5.1 Market Size, By Drugs, 2019-2026 (USD Billion)

6.3.5.2 Market Size, By Surgery, 2019-2026 (USD Billion)

6.3.6 France

6.3.6.1 Market Size, By Drugs, 2019-2026 (USD Billion)

6.3.6.2 Market Size, By Surgery, 2019-2026 (USD Billion)

6.3.7 Italy

6.3.7.1 Market Size, By Drugs, 2019-2026 (USD Billion)

6.3.7.2 Market Size, By Surgery, 2019-2026 (USD Billion)

6.3.8 Spain

6.3.8.1 Market Size, By Drugs, 2019-2026 (USD Billion)

6.3.8.2 Market Size, By Surgery, 2019-2026 (USD Billion)

6.3.9 Russia

6.3.9.1 Market Size, By Drugs, 2019-2026 (USD Billion)

6.3.9.2 Market Size, By Surgery, 2019-2026 (USD Billion)

6.4 Asia Pacific

6.4.1 Market Size, By Country 2019-2026 (USD Billion)

6.4.2 Market Size, By Drugs, 2019-2026 (USD Billion)

6.4.3 Market Size, By Surgery, 2019-2026 (USD Billion)

6.4.4 China

6.4.4.1 Market Size, By Drugs, 2019-2026 (USD Billion)

6.4.4.2 Market Size, By Surgery, 2019-2026 (USD Billion)

6.4.5 India

6.4.5.1 Market Size, By Drugs, 2019-2026 (USD Billion)

6.4.5.2 Market Size, By Surgery, 2019-2026 (USD Billion)

6.4.6 Japan

6.4.6.1 Market Size, By Drugs, 2019-2026 (USD Billion)

6.4.6.2 Market Size, By Surgery, 2019-2026 (USD Billion)

6.4.7 Australia

6.4.7.1 Market Size, By Drugs, 2019-2026 (USD Billion)

6.4.7.2 Market size, By Surgery, 2019-2026 (USD Billion)

6.4.8 South Korea

6.4.8.1 Market Size, By Drugs, 2019-2026 (USD Billion)

6.4.8.2 Market Size, By Surgery, 2019-2026 (USD Billion)

6.5 Latin America

6.5.1 Market Size, By Country 2019-2026 (USD Billion)

6.5.2 Market Size, By Drugs, 2019-2026 (USD Billion)

6.5.3 Market Size, By Surgery, 2019-2026 (USD Billion)

6.5.4 Brazil

6.5.4.1 Market Size, By Drugs, 2019-2026 (USD Billion)

6.5.4.2 Market Size, By Surgery, 2019-2026 (USD Billion)

6.5.5 Mexico

6.5.5.1 Market Size, By Drugs, 2019-2026 (USD Billion)

6.5.5.2 Market Size, By Surgery, 2019-2026 (USD Billion)

6.5.6 Argentina

6.5.6.1 Market Size, By Drugs, 2019-2026 (USD Billion)

6.5.6.2 Market Size, By Surgery, 2019-2026 (USD Billion)

6.6 MEA

6.6.1 Market Size, By Country 2019-2026 (USD Billion)

6.6.2 Market Size, By Drugs, 2019-2026 (USD Billion)

6.6.3 Market Size, By Surgery, 2019-2026 (USD Billion)

6.6.4 Saudi Arabia

6.6.4.1 Market Size, By Drugs, 2019-2026 (USD Billion)

6.6.4.2 Market Size, By Surgery, 2019-2026 (USD Billion)

6.6.5 UAE

6.6.5.1 Market Size, By Drugs, 2019-2026 (USD Billion)

6.6.5.2 Market Size, By Surgery, 2019-2026 (USD Billion)

6.6.6 South Africa

6.6.6.1 Market Size, By Drugs, 2019-2026 (USD Billion)

6.6.6.2 Market Size, By Surgery, 2019-2026 (USD Billion)

Chapter 7 Company Landscape

7.1 Competitive Analysis, 2020

7.2 Novartis AG

7.2.1 Company Overview

7.2.2 Financial Analysis

7.2.3 Strategic Positioning

7.2.4 Info-Graphic Analysis

7.3 AstraZeneca

7.3.1 Company Overview

7.3.2 Financial Analysis

7.3.3 Strategic Positioning

7.3.4 Info-Graphic Analysis

7.4 Merck & Co.

7.4.1 Company Overview

7.4.2 Financial Analysis

7.4.3 Strategic Positioning

7.4.4 Info-Graphic Analysis

7.5 Bayer AG

7.5.1 Company Overview

7.5.2 Financial Analysis

7.5.3 Strategic Positioning

7.5.4 Info-Graphic Analysis

7.6 Pfizer Inc.

7.6.1 Company Overview

7.6.2 Financial Analysis

7.6.3 Strategic Positioning

7.6.4 Info-Graphic Analysis

7.7 Teva Pharmaceutical Industries Ltd.

7.7.1 Company Overview

7.7.2 Financial Analysis

7.7.3 Strategic Positioning

7.7.4 Info-Graphic Analysis

7.8 Abbott Laboratories

7.8.1 Company Overview

7.8.2 Financial Analysis

7.8.3 Strategic Positioning

7.8.4 Info-Graphic Analysis

7.9 Sanofi S.A.

7.9.1 Company Overview

7.9.2 Financial Analysis

7.9.3 Strategic Positioning

7.9.4 Info-Graphic Analysis

7.10 Bristol Myers Squibb Company

7.10.1 Company Overview

7.10.2 Financial Analysis

7.10.3 Strategic Positioning

7.10.4 Info-Graphic Analysis

7.11 Ferring B.V.

7.11.1 Company Overview

7.11.2 Financial Analysis

7.11.3 Strategic Positioning

7.11.4 Info-Graphic Analysis

7.12 Other Companies

7.12.1 Company Overview

7.12.2 Financial Analysis

7.12.3 Strategic Positioning

7.12.4 Info-Graphic Analysis

The Global Polycystic Ovarian Syndrome Treatment Market has been studied from the year 2019 till 2026. However, the CAGR provided in the report is from the year 2021 to 2026. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.

The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Polycystic Ovarian Syndrome Treatment Market.

The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.

Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.

We value your investment and offer free customization with every report to fulfil your exact research needs.

This website is secure and your personal details are safe. Privacy

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

What is the projected market size of the global polycystic ovarian syndrome treatment market?

The global polycystic ovarian syndrome treatment market size is projected to grow at a CAGR of 5.2% during the forecast period (2021-2026).

Who are the major vendors in the polycystic ovarian syndrome treatment market?

Key and innovative vendors in the polycystic ovarian syndrome treatment market include Allergan plc, Pfizer Inc., Bayer AG, AstraZeneca plc., Bristol-Myers Squibb Company, Mylan N.V., Johnson and Johnson, Novartis AG, Teva Pharmaceutical Industries, and SANOFI.

Which region has the highest market share in the polycystic ovarian syndrome treatment market?

North America is estimated to hold the highest market share in the polycystic ovarian syndrome treatment market.

What is the Covid-19 impact on future polycystic ovarian syndrome treatment manufacturers?

Globally, the Covid-19 impact on the future polycystic ovarian syndrome treatment market will be quite significant for the manufacturers since demand has fluctuated owing to the lockdown in key nations throughout the world. North America would be leading because of the technical breakthroughs in the field of healthcare. Subsequently, Asia Pacific will be growing the fastest because of the increase in the number of target populations.

What are the major drivers in the polycystic ovarian syndrome treatment market?

The major driving factors for the polycystic ovarian syndrome treatment market include the rise in the rate of PCOS, increased patient awareness, increased use of standard treatment, the ease of access to PCOS therapies, the increase in demand for PCOS drugs, and technical advances in PCOS detection.